Early and Delayed Onset of Response to Antidepressants in Individual Trajectories of Change During Treatment of Major Depression: A Secondary Analysis of Data From the Genome-Based Therapeutic Drugs for Depression (GENDEP) Study

被引:110
作者
Uher, Rudolf [1 ]
Mors, Ole [2 ]
Rietschel, Marcella [3 ]
Rajewska-Rager, Aleksandra [4 ]
Petrovic, Ana [5 ]
Zobel, Astrid [6 ]
Henigsberg, Neven [7 ]
Mendlewicz, Julien [8 ]
Aitchison, Katherine J. [1 ]
Farmer, Anne [1 ]
McGuffin, Peter [1 ]
机构
[1] Kings Coll London, Inst Psychiat, MRC Social Genet & Dev Psychiat Res Ctr, London SE5 8AF, England
[2] Aarhus Univ Hosp, Ctr Psychiat Res, Risskov, Denmark
[3] Cent Inst Mental Hlth, Div Genet Epidemiol Psychiat, D-6800 Mannheim, Germany
[4] Poznan Univ Med Sci, Dept Psychiat, Poznan, Poland
[5] Inst Publ Hlth, Ljubljana, Slovenia
[6] Univ Bonn, D-5300 Bonn, Germany
[7] Univ Zagreb, Sch Med, Croatian Inst Brain Res, Zagreb 41001, Croatia
[8] Free Univ Brussels, B-1050 Brussels, Belgium
关键词
1ST; 2; WEEKS; EARLY IMPROVEMENT; GUIDELINES; NORTRIPTYLINE; ESCITALOPRAM; DISORDERS; NUMBER;
D O I
10.4088/JCP.10m06419
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Objective:The timing and rate of improvement after the initiation of an antidepressant has implications for establishing the mechanism of antidepressant action and for answering the clinically relevant question of how long an appropriate trial of antidepressant medication should be. We explore the individual trajectories of relative change in depression severity to establish what proportion of individuals experience early and late onset of improvement. Method: Longitudinal latent class analysis was applied in a secondary analysis of data obtained from the Genome-Based Therapeutic Drugs for Depression (GENDEP) study. In the GENDEP trial, conducted in 9 European academic psychiatry centers from July 2004 to June 2008, 811 treatment-seeking adult subjects with DSM-IV major depression received escitalopram or nortriptyline for 12 weeks. Montgomery-Asberg Depression Rating Scale measurements were taken weekly. The secondary analysis reported in this article was conducted in 2010. Results: A model with 9 latent classes provided a good description of the individual trajectories of symptom change over time. These classes included 3 nonresponder classes, 3 classes with varying degrees of improvement concentrated in the first 3 weeks (early improvement), and 3 classes with varying degrees of improvement that was more prominent in the second 3 weeks than in the first 3 weeks (delayed improvement). More than half of the subjects who eventually reached remission showed a pattern of delayed improvement, and their eventual outcome could not be predicted from early time points. Early marked response occurred more frequently in subjects treated with nortriptyline than in those treated with escitalopram (12.9% vs 7.5%, chi(2) = 6.29, P = .01). Delayed complete remission occurred more frequently in subjects treated with escitalopram than in those treated with nortriptyline (13.6% vs 6.1%, chi(2) = 11.52, P = .0007). Conclusions: Both early and delayed improvement are common. Although early changes are maintained, the eventual outcome of 12-week antidepressant treatment can be accurately predicted only after 8 weeks.
引用
收藏
页码:1478 / 1484
页数:7
相关论文
共 39 条
  • [1] Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines
    Anderson, I. M.
    Ferrier, I. N.
    Baldwin, R. C.
    Cowen, P. J.
    Howard, L.
    Lewis, G.
    Matthews, K.
    McAllister-Williams, R. H.
    Peveler, R. C.
    Scott, J.
    Tylee, A.
    [J]. JOURNAL OF PSYCHOPHARMACOLOGY, 2008, 22 (04) : 343 - 396
  • [2] World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care
    Bauer, Michael
    Bschor, Tom
    Pfennig, Andrea
    Whybrow, Peter C.
    Angst, Jules
    Versiani, Marcio
    Moeller, Hans-Juergen
    [J]. WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2007, 8 (02) : 67 - 104
  • [3] An entropy criterion for assessing the number of clusters in a mixture model
    Celeux, G
    Soromenho, G
    [J]. JOURNAL OF CLASSIFICATION, 1996, 13 (02) : 195 - 212
  • [4] The course of depressive symptoms in unipolar depressive disorder during electroconvulsive therapy: A latent class analysis
    Cinar, S.
    Voshaar, R. C. Oude
    Janzing, J. G. E.
    Birkenhager, T. K.
    Buitelaar, J. K.
    van den Broek, W. W.
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2010, 124 (1-2) : 141 - 147
  • [5] Antidepressant response trajectories and quantitative electroencephalography (QEEG) biomarkers in major depressive disorder
    Hunter, Aimee M.
    Muthen, Bengt O.
    Cook, Ian A.
    Leuchter, Andrew F.
    [J]. JOURNAL OF PSYCHIATRIC RESEARCH, 2010, 44 (02) : 90 - 98
  • [6] Katz M M, 1996, Depress Anxiety, V4, P257, DOI 10.1002/(SICI)1520-6394(1996)4:6<257::AID-DA1>3.3.CO
  • [7] 2-C
  • [8] Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. Ill. Pharmacotherapy
    Lam, Raymond W.
    Kennedy, Sidney H.
    Grigoriadis, Sophie
    McIntyre, Roger S.
    Milev, Roumen
    Ramasubbu, Rajamannar
    Parikh, Sagar V.
    Patten, Scott B.
    Ravindran, Arun V.
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2009, 117 : S26 - S43
  • [9] Handling drop-out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches
    Lane, Peter
    [J]. PHARMACEUTICAL STATISTICS, 2008, 7 (02) : 93 - 106
  • [10] Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder
    Leuchter, Andrew F.
    Cook, Ian A.
    Gilmer, William S.
    Marangell, Lauren B.
    Burgoyne, Karl S.
    Howland, Robert H.
    Trivedi, Madhukar H.
    Zisook, Sidney
    Jain, Rakesh
    Fava, Maurizio
    Iosifescu, Dan
    Greenwald, Scott
    [J]. PSYCHIATRY RESEARCH, 2009, 169 (02) : 132 - 138